Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Greg Rich who wrote (597)	4/26/2000 5:28:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Greg, I would like to think our wait for clinical results for Zomaril are not that far away. Nice action in the stock today, and IMO these levels are not going to be available for investors interested in TTP for much longer. I HOPE! I HOPE!

To: Greg Rich who wrote (597)	4/27/2000 12:30:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Lazard starts new coverage on my favorite biotech...I assume this is what has the stock up this morning...only wish there was more volume...-- Titan Pharmaceuticals (Amex: TTP), $25.125, with a "BUY" rating and a 12-month price target of $46. In his report, Mr. Sendek noted that Titan meets all of Lazard's investment criteria for a development-stage biotech company: strong, late-stage products addressing large markets; multiple pharmaceutical partners; and a strong cash position. Titan's most advanced product, Zomaril, is in Phase III testing for schizophrenia in collaboration with Novartis.